Bulk Inquiry
MLN9708
- Ixazomib citrate
Axon 2557
CAS:
1201902-80-8
Purity:
99%
- Soluble in DMSO
- MF: C20H23BCl2N2O9
- MW: 517.12
Description
Citrate prodrug of MLN2238 (Ixazomib; Axon 2556), a selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN9708 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models. Approved by the FDA in November 2015 for multiple myeloma treatment.
More Information
| Parent CAS No. | 1201902-80-8 |
|---|---|
| Chemical Name | 4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid |
| MFCD | MFCD18251437 |
| Short Description | Proteasome inhibitor |
References
- E Kupperman et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.Cancer Res. 2010 Mar 1;70(5):1970-80.
- JJ Gu et al. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive….Anticancer Drugs. 2013 Nov;24(10):1030-8.
- N Shah et al. Ixazomib: an oral proteasome inhibitor for the treatment of multiple myeloma. Exp. Opin. Orph. Drugs (2016), 4(1), 105-113.
Other Categories
Get a Quote for
Loading...